

LIFE SCIENCES SALES PIPELINE EXPANSION FOLLOWING ADLM 2026

BRISBANE, AUSTRALIA, 24 August 2026: AnteoTech Ltd (ASX: ADO) ('AnteoTech' or 'the Company') is an Australian-based supplier of advanced chemical and material solutions to the global battery and life sciences markets. The Company uses its proprietary, patented cross-linking chemical platform technology to develop and commercialise surface modification solutions designed to improve product performance and lower end-product costs. The Company is pleased to provide an update on its Life Sciences business following its recent attendance at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 conference in Anaheim, California, USA.

Key points:

- AnteoTech's Life Sciences team recently attended the Association for Diagnostics & Laboratory Medicine ("ADLM") 2026 Conference, engaging with diagnostic test and particle manufacturers, diagnostic platform developers and researchers from the global immunoassay and diagnostics industry.
- Leads generated through ADLM 2026 have tripled the Life Sciences sales pipeline, in overall lead terms. Eleven pre-arranged meetings were held, more than 80 visits were made to AnteoTech's booth and 18 follow-up meetings with sales qualified leads (SQLs) have since been held.
- Seven AnteoBind™ NXT samples have been requested as a result and will be dispatched by the end of August, with further meetings planned and follow ups underway.
- A number of companies already familiar with AnteoBind™ through longstanding relationships re-engaged at ADLM and have recommenced work with AnteoTech. Interest was largely received in AnteoBind™ for lateral flow applications and ELISA plate activation, with 5 requests for activated ELISA plates received.
- AnteoTech intends to undertake independent third-party validation testing of new lateral flow, multiplex and chemiluminescence (CLIA) applications. While at ADLM the Company advanced discussions with qualified independent testing providers to support this objective. Validation work programs are currently being scoped.
- AnteoTech CLIA Kits were launched and showcased at ADLM. CLIA has become an indispensable tool in modern laboratories due to its high sensitivity, specificity and automation potential enabling low cost diagnostics. AnteoBind CLIA Kits include optimised activation protocols for activation and deliver enhanced performance and improved workflows. Work on sales channels for these kits is progressing.
- Follow-up activity is focused on progressing leads via technical meetings and sample supply, customer testing discussions and potential sales conversion negotiations.
- AnteoTech will host expert-led product webinars next month showcasing real-world AnteoBind™ use cases across immunoassay and diagnostic test applications.

MERRILL GRAY, MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER OF ANTEOTECH COMMENTED:

"ADLM was a valuable event for AnteoTech, giving us direct access to diagnostic test manufacturers, developers and platform providers. We generated new leads, re-engaged with longstanding contacts and saw strong interest in AnteoBind™, particularly across lateral flow applications, our cornerstone application area, and our new ELISA plate activation offering".

“The important work now is the follow-up. We already have 18 post-ADLM meetings completed, seven AnteoBind™ NXT samples for use in various test development applications requested, and further meetings planned, in addition to our other sales activities. We are also progressing discussions with large particle manufacturers and diagnostic contract manufacturers in the USA, Japan and UK who we engaged with at ADLM”.

“We will be taking all of our learnings and insights from ADLM to the Medica Conference (16 to 19 November 2026) in Germany”.

“Our focus for the remainder of CY2026 is to systematically progress our pipeline opportunities through customer testing and evaluation and work towards converting them into sales”.

ADLM 2026 EXPANDS LIFE SCIENCES CUSTOMER ENGAGEMENT

AnteoTech's Life Sciences team attended ADLM 2026, one of the largest global gatherings of diagnostics and laboratory medicine professionals, bringing together test manufacturers, particle manufacturers, instrument makers and platform technology providers from across the immunoassay industry. More than 700 companies exhibited and almost 17,000 people attended.¹

The team held nine pre-arranged meetings, and more than 80 companies visited the AnteoTech booth and showed interest in AnteoTech's offerings and technologies. Since the conference, 18 follow-up meetings have been held and seven AnteoBind™ NXT samples have been requested for dispatch by the end of August 2026, with further meetings planned.

Discussions were also initiated with several large global life sciences companies including diagnostic equipment manufacturers and magnetic particle manufacturers regarding potential collaboration opportunities involving AnteoBind™ NXT. The Company continues to assess joint product development opportunities as part of its strategy to move further up the immunoassay value chain.

The team also re-engaged with a number of longstanding contacts already familiar with AnteoBind™. Several of these organisations have agreed to recommence or expand activities with AnteoTech, building on established relationships and technical familiarity with the technology.

Figure 1: The AnteoTech Life Sciences Booth and Team at ADLM 2026.



¹ <https://myadlm.org/media/press-release-archive/2026/07-july/adlm-announces-2026-top-corporate-supporter-award-recipients>

INDEPENDENT THIRD-PARTY VALIDATION PROGRESS

AnteoTech has identified and engaged with organisations in the USA and UK capable of providing independent third-party validation of AnteoBind™ performance data.

This work is intended to strengthen the evidence supporting AnteoBind™ performance claims for prospective customers and partners. Validation programs are currently being scoped across lateral flow, multiplex and chemiluminescence (CLIA) applications, with testing expected to commence shortly.

LATERAL FLOW, ELISA AND CLIA APPLICATIONS

ADLM attendees showed strong interest in AnteoBind™ applications in lateral flow and ELISA plate activation. Several samples of AnteoTech's pre-activated ELISA plates were requested for customer evaluation and will be provided over the coming quarter.

The Company has extensive experience in proof-of-concept development for lateral flow applications and provides commercialisation design services based on this experience.

For ELISA, AnteoTech is at prototype stage of development of pre-activated plates designed to provide a lower-cost alternative to premium high-binding ELISA plates while maintaining comparable assay performance. Validation with multiple plate manufacturers is underway to support broader commercial deployment and potential strategic partnerships.

AnteoTech's CLIA Kits which bundle a range of magnetic particles which can be activated using AnteoBind™ NXT and include optimised activation protocols, were launched and showcased with interest received. Work on sales channels for these kits is progressing.

UPCOMING ANTEOBIND™ USE CASE WEBINARS

AnteoTech will host a series of webinars featuring diagnostic assay and platform development experts, showcasing real-world AnteoBind™ use cases across immunoassay and diagnostic applications.

The webinars will demonstrate how AnteoBind™ has been used to address immobilisation and performance challenges in immunoassay development, supporting the Company's broader sales and marketing activities. Further details, including dates and confirmed speakers, will be provided in due course.

The Life Sciences team will continue to progress the customer discussions, sample evaluations and relationships generated or re-established through ADLM 2026, with a focus on converting these opportunities into sales.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - (ASX: ADO)

AnteoTech is a supplier of advanced chemical and material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemical platform technology to develop and commercialise solutions for our global customer base. From our patented high silicon anode cross linker product Anteo X™ to our ceramic coated separator product Anteo S™ and our Collector foil primer coating performance additive Anteo C through to our next-generation high silicon anode formulations Ultranode™ 70, 95 and X our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable advanced chemicals and materials within the global Lithium ion Battery (LiB) market. Our Life Sciences business supplies advanced materials activated by our chemicals, to leading developers and manufacturers of vaccines and diagnostic tests utilising our AnteoBind™ suite of products. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' and other immunoassay diagnostic tests, such as Chemiluminescence immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) plates, AnteoBind™ NXT enables faster, more reliable and more accurate test results wherever they are needed.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.